Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 117

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 117
---
 commercial needs, if any;                                      |

| • |     | Contract manufacturers may not be able to execute TuHURA’s manufacturing procedures and other logistical 
 support requirements appropriately;                                                                      |

| • |     | TuHURA’s future contract manufacturers may not perform as agreed, may not devote sufficient resources to its                                                                           
 products, or may not remain in the contract manufacturing business for the time required to supply its clinical trials or to successfully produce, store, and distribute its products; |

| • |     | TuHURA’s future contract manufacturers may not perform as agreed, may not devote sufficient resources to its                                                                           
 products, or may not remain in the contract manufacturing business for the time required to supply its clinical trials or to successfully produce, store, and distribute its products; |

| • |     | Manufacturers are subject to ongoing periodic unannounced inspection by the FDA and corresponding state agencies 
 to ensure strict compliance with current good manufacturing practices, or cGMP, current                          |

| • |     | good tissue practices, or cGTP, if applicable and other government regulations and corresponding foreign                 
 standards. TuHURA does not have control over third-party manufacturers’ compliance with these regulations and standards; |

| • |     | TuHURA may not own, or may not solely own, the intellectual property rights to improvements made by its 
 third-party manufacturers in the manufacturing process for its products;                                |

| • |     | TuHURA’s third-party manufacturers could breach or terminate their agreement with the company; |

| • |     | Raw materials and components used in the manufacturing process, particularly those for which TuHURA has no other            
 source or supplier, may not be available or may not be suitable or acceptable for use due to material or component defects; |

70

| • |     | TuHURA’s contract manufacturers and critical reagent suppliers may be subject to inclement weather, as well 
 as natural or man-made disasters; and                                                                       |

| • |     | TuHURA’s contract manufacturers may have unacceptable or inconsistent product quality success rates and 
 yields.                                                                                                 |

Each of these risks could delay or prevent the completion of TuHURA’s clinical trials or the approval of any of its product candidates by the FDA, result in higher costs or adversely impact commercialization of TuHURA’s product candidates. In addition, TuHURA will rely on third parties to perform certain specification tests on its product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable,